Cynata Expands trial in COVID-19 & Respiratory Failure
Filed with ASX · · 12 pages · English
Melbourne, Australia; 29 March 2021: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to expand recruitment criteria in its active MEND (MEseNchymal coviD-19) clinical trial. Key highlights • Ethics committee approval received to expand the recruitment criteria of
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs
- Cynata Therapeutics Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte
- Cynata Receives $1.39m R&D Tax Incentive Refund
- Completion of Entitlement Offer and Shortfall Placement
- Offer Booklet and Entitlement & Acceptance Form
Later from Cynata Therapeutics
- Cynata Therapeutics Expands MEND clinical trial in COVID-19 and Respiratory Failure
- First Patient Enrolled in Cynata MEND Clinical Trial
- Cynata signs Licence Agreement with TekCyte
- Progress Toward Clinical Trial in Diabetic Foot Ulcers
- Ethics Approval for Cynatas Clinical Trial in DFU
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics